A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome

Meral Beksaç; Güldane Cengiz Seval; Nicholas Kanellias; Daniel Coriu; Laura Rosiñol; Gülsüm Özet; Vesselina Goranova‐Marinova; Ali Ekrem Ünal; Jelena Bila; Hayri Özsan; Arben Ivanaj; Lejla Ibricevic Balić; Efstathios Kastritis; Joan Bladé; Meletios A Dimopoulos

doi:10.3324/haematol.2020.278272

Article2019

A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome

Meral Beksaç, Güldane Cengiz Seval, Nicholas Kanellias, Daniel Coriu, Laura Rosiñol, Gülsüm Özet, Vesselina Goranova‐Marinova, Ali Ünal, Jelena Bila, Hayri Özsan, Arben Ivanaj, Lejla Ibricevic Balić, Efstathios Kastritis, Joan Bladé, Meletios A Dimopoulos

Article2024

Real-World Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with Teclistamab and Talquetamab; A Multicenter Analysis from the Greek Myeloma Study Group

Ioannis Ntanasis‐Stathopoulos, Eirini Katodrytou, Evdoxia Hatjiharissi, Emmanouil Spanoudakis, Vasiliki Douka, Despina Fotiou, Vasiliki Labropoulou, Dimitra Dalampira, Vasiliki Spiliopoulou, Theodosia Papadopoulou, Dimitrios Christoulas, Panagiotis Malandrakis, Anthi Bouchla, Vasiliki Pappa, Efstathios Kastritis, Evangelos Terpos, Meletios A Dimopoulos, Maria Gavriatopoulou

Article2018

Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group

Eirini Katodritou, Evangelos Terpos, Sossana Delimpasi, Maria Kotsopoulou, Eurydiki Michalis, Chrysanthi Vadikolia, Marie‐Christine Kyrtsonis, Argiris Symeonidis, Nikolaos Giannakoulas, Chrissa Vadikolia, Michalis Michael, Christina Kalpadakis, Theodora Gougopoulou, Chrystalla Prokopiou, Georgia Kaiafa, Dimitrios Christoulas, Maria Gavriatopoulou, Evlampia Giannopoulou, Vasiliki Labropoulou, Evgenia Verrou, Efstathios Kastritis, ,

Article2023

Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)

Clara Grazia Chisari, Assunta Bianco, Vincenzo Brescia Morra, Massimiliano Calabrese, Fioravante Capone, Paola Cavalla, Carlotta Chiavazza, Cristoforo Comi, Maura Danni, Massimo Filippi, Pietro Iaffaldano, Roberta Lanzillo, Salvatore Lo Fermo, Alessandra Lucisano, Alessandra Lugaresi, Giacomo Lus, Gerolama Alessandra Marfia, Fabiana Marinelli, Massimiliano Mirabella, Lucia Moiola, Chiara Perin, Sabrina Realmuto,

Article2025

Disease Characteristics and Treatment Outcomes of Myeloma Patients Under 50 Years of Age: An Analysis of the Balkan Myeloma Study Group

Despina Fotiou, Sorina Bădeliță, Eirini Katodritou, Meral Beksaç, Jelena Bila, Emmanouil Spanoudakis, Josip Batinić, Daniel Coriu, Sinziana Barbu, Catalin Danaı̈la, Dimitra Dalampira, Angeliki Sevastoudi, Güldane Cengiz Seval, Selami Koçak Toprak, Aleksandra Sretenović, Olivera Marković, Toni Valković, Zorica Cvetković, Fenia Theodorakakou, Maria Gavriatopoulou, Evangelos Terpos, Meletios A Dimopoulos,

A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome

Abstract

Discussion(0)

Related publications

A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome

Real-World Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with Teclistamab and Talquetamab; A Multicenter Analysis from the Greek Myeloma Study Group

Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group

Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)

Disease Characteristics and Treatment Outcomes of Myeloma Patients Under 50 Years of Age: An Analysis of the Balkan Myeloma Study Group